Jia Longgang, Wang Ruijia, Lu Wanbo, Sun Hui, Huang Zhiqi, Wang Hongbin, Lu Fuping, Liu Yihan
Key Laboratory of Industrial Fermentation Microbiology, Ministry of Education, Tianjin Key Laboratory of Industrial Microbiology, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, People's Republic of China.
College of Food Science and Engineering, Tianjin University of Science and Technology, Tianjin, People's Republic of China.
J Food Sci. 2025 Aug;90(8):e70335. doi: 10.1111/1750-3841.70335.
Obesity has emerged as a prevalent clinical and public health concern in contemporary society, imposing significant economic and social burdens worldwide. Phosphatidylserine (PS), a functionally diverse phospholipid, demonstrates multiple biological activities. This study delves into the efficacy and underlying mechanisms of PS in mitigating high-fat diet (HFD)-induced obesity in mice. Comprehensive physiological and biochemical assessments revealed that both preventive and therapeutic interventions with PS effectively attenuated lipid accumulation, liver dysfunction, and obesity associated with HFD consumption. Metabolomic analyses further illuminated that HFD mice hepatic cholic acid (CA), β-muricholic acid (β-MCA), and deoxycholic acid (DCA) contents were significantly decreased by 42.5%-58.5%, 66.4%-69.0%, and 11.0%-12.2%, respectively, after PS administration. And serum α-muricholic acid (α-MCA) and ω-muricholic acid (ω-MCA) were also significantly reduced by 19.2%-23.4% and 9.3%-11.5%, respectively. 16S rDNA sequencing highlighted the modulatory effects of PS on gut microbiota composition in HFD mice. Specifically, PS treatment positively correlated with the abundance of Alloprevotella and inversely correlated with Parasutterella, Olsenella, and Allobaculum, suggesting a targeted modulation of the gut microbial ecosystem. In summary, this study highlights the therapeutic potential of PS in mitigating HFD-induced obesity through modulation of bile acid metabolism and gut microbiota composition. These findings provide a scientific foundation for further exploration of PS as a viable nutraceutical or therapeutic agent in obesity intervention strategies.
肥胖已成为当代社会普遍存在的临床和公共卫生问题，在全球范围内造成了重大的经济和社会负担。磷脂酰丝氨酸（PS）是一种功能多样的磷脂，具有多种生物活性。本研究探讨了PS减轻高脂饮食（HFD）诱导的小鼠肥胖的功效及其潜在机制。全面的生理和生化评估表明，PS的预防性和治疗性干预均能有效减轻与HFD摄入相关的脂质积累、肝功能障碍和肥胖。代谢组学分析进一步表明，给予PS后，HFD小鼠肝脏中的胆酸（CA）、β-鼠胆酸（β-MCA）和脱氧胆酸（DCA）含量分别显著降低了42.5%-58.5%、66.4%-69.0%和11.0%-12.2%。血清α-鼠胆酸（α-MCA）和ω-鼠胆酸（ω-MCA）也分别显著降低了19.2%-23.4%和9.3%-11.5%。16S rDNA测序突出了PS对HFD小鼠肠道微生物群组成的调节作用。具体而言，PS治疗与Alloprevotella的丰度呈正相关，与Parasutterella、Olsenella和Allobaculum呈负相关，表明对肠道微生物生态系统有针对性的调节。总之，本研究强调了PS通过调节胆汁酸代谢和肠道微生物群组成减轻HFD诱导的肥胖的治疗潜力。这些发现为进一步探索PS作为肥胖干预策略中一种可行的营养保健品或治疗剂提供了科学依据。
